LENZ Therapeutics, Inc.

Ladies and gentlemen, and welcome to the Lent Therapeutics Year-End 2025 Financial Rituals Conference Call. At this time, all participants are in a distant old mood. While we prepare remarks for management, we will conduct a question and answer session, and instructions will follow at that time. As a reminder, the call is being recorded. At this time, I would like to turn the call over to Dan Chandler, State Financial Officer. Please go ahead.

Thank you. Good morning, and thank you for joining us today.

My name is Dan Chevalard, Chief Financial Officer of Lens Therapeutics. We are joined today by Abe Stummel-Pennick, our President and Chief Executive Officer, and Shawn Olson, our Chief Commercial Officer, as well as Dr. Mark Odrich, Chief Medical Officer, who will join us for the question and answer session. Before we begin, I would like to remind you that this call will contain forward-looking statements regarding Lens' future expectations, plans, prospects, corporate strategy, regulatory and commercial plans and expectations, cash runway projections, and performance. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors and risks, including those discussed in our filings with the SEC and which can also be found on our website. In addition, any forward-looking statements represent only our views as of the date of this broadcast and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligations to update such statements. The company encourages you to consult the risk factors contained in our ICT filings for additional detail, including in our 2025 Form 10-K, which will be filed later today. With that, I'll now turn the call over to Abe.